Document Detail


Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.
MedLine Citation:
PMID:  9363724     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The efficacy of the luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) in the medical management of uterine leiomyomas (fibromas) was evaluated. Cetrorelix was administered to 18 pre-menopausal women with myomas with a mean age of 33.3 years, who had been candidates for hysterectomy. The initial dose of Cetrorelix was 5 mg twice daily s.c. for the first 2 days and thereafter 0.8 mg was given twice daily s.c. for at least 3 months. The mean duration of the treatment was 4.4 months. Before the therapy with Cetrorelix, the mean uterine volume, measured by ultrasonography, was 395.4 +/- 69.2 ml (range 89-1166). Sixteen patients showed a progressive reduction in uterine volume from 410.4 +/- 77.1 to a mean of 230.8 +/- 52.6 ml at 3 months. All patients became amenorrhoeic and had hot flushes. After treatment with Cetrorelix, a surgical myomectomy was performed in 12 women. One of the patients subjected to myomectomy after therapy with Cetrorelix became pregnant. These patients have been followed for up to 25 months and only in one case has the uterine volume increased after therapy. Three patients had good responses to therapy with Cetrorelix and it was decided to follow them only by observation. One patient became pregnant 2 months later. In the other patient, the uterine volume remained unchanged for the duration of the follow-up of 2 years and the third patient showed an increase after 21 months. In three patients, it was necessary to perform total hysterectomy. In 14 patients, serum concentrations of luteinizing hormone, follicle stimulating hormone and oestradiol decreased after the administration of the first dose of Cetrorelix and continued at subnormal values throughout therapy. In 15 patients who were not subjected to total hysterectomy, menstrual function returned at 1 month after cessation of treatment. Overall results support the use of Cetrorelix for the management of uterine leiomyomas.
Authors:
D Gonzalez-Barcena; R B Alvarez; E P Ochoa; I C Cornejo; A M Comaru-Schally; A V Schally; J Engel; T Reissmann; H Riethmüller-Winzen
Related Documents :
12615834 - Analysis of intra-uterine cytokine concentration and matrix-metalloproteinase activity ...
1308424 - Danazol. a new perspective in the treatment of htlv-1 associated myelopathy (preliminar...
12524074 - The ontario uterine fibroid embolization trial. part 2. uterine fibroid reduction and s...
22527434 - Biophysical evaluation of fractional laser skin resurfacing with an er:ysgg laser devic...
20679774 - Deep anaesthesia reduces postoperative analgesic requirements after major urological pr...
11900664 - Emergency treatment of craniocerebral firearm wounds.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Human reproduction (Oxford, England)     Volume:  12     ISSN:  0268-1161     ISO Abbreviation:  Hum. Reprod.     Publication Date:  1997 Sep 
Date Detail:
Created Date:  1997-12-05     Completed Date:  1997-12-05     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8701199     Medline TA:  Hum Reprod     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  2028-35     Citation Subset:  IM    
Affiliation:
The Hospital de Especialidades Centro Médico La Raza - IMSS, Mexico.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Female
Follicular Phase
Gonadotropin-Releasing Hormone / administration & dosage,  analogs & derivatives*,  antagonists & inhibitors*,  therapeutic use
Hormone Antagonists / therapeutic use*
Humans
Hysterectomy
Leiomyoma / drug therapy*,  surgery,  ultrasonography
Luteal Phase
Middle Aged
Pregnancy
Uterine Hemorrhage
Uterine Neoplasms / drug therapy*,  surgery,  ultrasonography
Uterus / ultrasonography
Chemical
Reg. No./Substance:
0/Hormone Antagonists; 33515-09-2/Gonadotropin-Releasing Hormone; OON1HFZ4BA/cetrorelix
Comments/Corrections
Comment In:
Hum Reprod. 2000 Sep;15(9):2059-61   [PMID:  10967015 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Carrier-specific breakpoint-spanning DNA probes: an approach to preimplantation genetic diagnosis in...
Next Document:  Endothelin and neutral endopeptidase in the endometrium of women with menorrhagia.